ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2951

Responsiveness of the Patient Reported Outcomes Measurement Information System to Golimumab Intravenous and Infliximab Treatment in a Real World Clinical Trial in Rheumatoid Arthritis Patients

Jeffrey R. Curtis1, Douglas Conaway2, Joy Schechtman3, Aaron Broadwell4, Alan J. Kivitz5, Vance Bray6, Shelly Kafka7, Dennis Parenti7, Shawn Black7, Stephen Xu8, Wayne Langholff8 and Clifton O. Bingham III9, 1Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology/Medicine, Carolina Health Specialists, Myrtle Beach, SC, 3Sun Valley Arthritis Center LTD, Peoria, AZ, 4Rheumatology Osteoporosis Specialists, Shreveport, LA, 5Altoona Arthritis & Osteoporosis Center, Altoona, PA, 6Denver Arthritis Clinic, Denver, CO, 7Janssen Scientific Affairs, LLC, Horsham, PA, 8Janssen Research & Development, LLC, Spring House, PA, 9Rheumatology, Johns Hopkins University, Baltimore, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Assessment, Biologics, patient outcomes and rheumatoid arthritis (RA), PROMIS

  • Tweet
  • Email
  • Print
Session Information

Date: Wednesday, November 8, 2017

Session Title: Patient Outcomes, Preferences, and Attitudes III

Session Type: ACR Concurrent Abstract Session

Session Time: 11:00AM-12:30PM

Background/Purpose: The Patient (Pt) Reported Outcomes Measurement Information System (PROMIS [P]) questionnaires developed by the NIH have been validated and are a feasible assessment tool for rheumatoid arthritis (RA) patients (pts) (Bartlett 2015). AWARE (Comparative and Pragmatic Study of Golimumab Intravenous [IV] Versus Infliximab in RA) is a large, pragmatic multi-center United States based, real-world evidence study of golimumab IV (GLM) vs. infliximab (IFX) in RA, and is using PROMIS assessments as one measure of pt response to therapy. Here we report interim results of the responsiveness of multiple PROMIS short forms and profiles with treatment of RA using GLM or IFX.

Methods: AWARE is a prospective, noninterventional study in which 1,200 adult pts will be enrolled upon initiation of treatment with GLM or IFX. PRO assessments of pt response to treatment include use of PROMIS-29 Profile v2.0 (P29v2), P Pain Interference Short Form-6b (SF6b) and P Fatigue Short Form-7a (SF7a), 36-Item Short Form Health Survey (SF-36v2) and the Clinical Disease Activity Index (CDAI). We report results of an interim analysis of pt response to PROMIS questionnaires. PROMIS questionnaire results are normalized to the US population and reported as a “T-score” (mean of 50 and standard deviation (SD) of 10). Data shown are mean ± standard deviation baseline score (month 0) and change from baseline (months 2 and 5), and interpreted as an effect size.

Results: GLM pts were 61.0 ± 13.0 years and IFX pts were 57.2 ± 13.0 years. RA disease duration of GLM pts was 9.0 ± 9.3 years and IFX pts was 6.8 ± 9.7 years. Mean baseline CDAI score for GLM pts was 31.1 ± 14.6 and for IFX pts was 34.3 ±16.2. with most starting in high (71.4% GLM/72.0% IFX) or moderate disease activity (21.8% GLM/23.4% IFX). A total of 573-586 pts contributed data at the 2 month time point, and 169-173 pts at the 5 month time point. PROMIS domain T-scores of GLM and IFX pts at baseline and mean change from baseline are shown (Table). The mean changes in PROMIS T-scores were generally in the 1-4 unit range, consistent with a small to moderate size effect, with all mean changes in the expected direction that reflected clinical improvement.

PROMIS Domain  

Mon. of Tx

GLM

IFX

PROMIS Domain

Mon. of Tx

GLM

IFX

 

 

Mean (SD)

N

Mean (SD)

N

 

 

Mean (SD)

N

Mean (SD)

N

Fatigue SF7a

0

 59.4 (8.5)

377

 59.2 (8.6)

305

Fatigue P29v2

0

 58.7 (9.7)

369

 59.0 (10.2)

304

2

 -1.9 (6.1)

317

 -1.1 (5.5)

269

2

 -1.6 (7.0)

307

 -1.7 (7.0)

266

5

 -2.3 (6.0)

74

 -2.7 (6.6) 

101

5

 -2.6 (7.5)

72

 -3.6 (8.1)

98

Pain Interference SF 6b

0

 62.2 (7.6)

376

 62.9 (7.5)

306

Physical Function P29v2

0

 37.8 (6.2)

373

 38.1 (7.0)

302

2

 -2.4 (5.7)

319

 -2.6 (5.9)

270

2

  1.1 (4.6)

312

  0.8 (4.7)

262

5

 -3.3 (6.9)

74

 -3.8 (6.7)  

101

5

  2.3 (4.7)

71

  2.2 (5.7)

100

Pain Interference P29v2

0

 63.2 (7.8)

376

 63.9 (7.5)

305

Sleep Disturbance P29v2

0

 55.0 (8.6)

371

 56.1 (8.9)

301

2

 -2.6 (6.6)

319

 -2.6 (6.6)

267

2

 -1.4 (6.5)

312

 -1.3 (6.7)

262

5

 -2.4 (6.9)

73

 -3.7 (7.6)

100

5

 -1.8 (7.9)

71

 -3.0 (7.3)

98

Depression P29v2

0

 52.3 (10.1)

372

 52.6 (10.6)

305

Ability to Participate Social Roles P29v2

0

 43.4 (8.4)

371

 42.8 (8.9)

304

2

 -1.3 (6.8)

315

 -1.6 (6.6)

266

2

  1.6 (6.2)

314

  0.7 (5.7)

266

5

 -2.9 (6.9)

72

 -2.3 (8.4)

101

5

  3.0 (6.8)

70

  2.2 (6.6)

100

Anxiety P29v2

0

 53.3 (10.3)

372

 54.5 (10.5)

302

Pain Intensity P29v2 (0-10 unit scale)

0

  6.0 (2.3)

371

  6.1 (2.1)

304

2

 -1.3 (7.6)

316

 -2.0 (7.0)

262

2

 -0.9 (2.0)

314

 -0.9 (1.9)

266

5

 -2.4 (7.5)

72

 -2.9 (9.4)

101

5

 -1.0 (2.5)

71

 -1.2 (2.2)

98

Mon. = Month, Tx = Treatment

Conclusion: These interim data support the use of PROMIS questionnaires to evaluate RA pts in trials and to measure improvement across a range of domains. As additional pts reach later time points (future interim analyses and primary endpoint assessment), the magnitude of change will become more apparent. Analyses using the fully enrolled AWARE study evaluated over 3 years and analysis of PROMIS changes relative to other outcome measures will further define the practical utilization of PROMIS in RA pts.


Disclosure: J. R. Curtis, AbbVie, Roche/Genentech, BMS, UCB, Myraid, Lilly, Amgen, Janssen, Pfizer, Corrona, 5,Amgen, Pfizer, Crescendo Bio, Corrona, 9; D. Conaway, Amgen, Crescendo Bioscience, AbbVie, BMS, CSRO, Interstate Postgraduate Medical Association, Pfizer, Janssen, 8,Crescendo, Janssen, 2,Janssen, 6,Interstate Postgraduate Medical Association, 9; J. Schechtman, None; A. Broadwell, AbbVie, Amgen, Janssen, Celgene, Pfizer, Mallinckrodt, UCB, 8,Amgen, Janssen, Pfizer, 5,Janssen, 2; A. J. Kivitz, Amgen, AbbVie, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, UCB, Genzyme,Sanofi, Regeneron, Vertex, 8,Amgen, AbbVie, Celgene, Genentech, Janssen, Merck, Novartis, Pfizer, UCB, Genzyme,Sanofi, Regeneron, Vertex, 5; V. Bray, Janssen, AbbVie, Lilly, Astra Zeneca, Gilead, Sun, R Pharm, 2; S. Kafka, Janssen, 3,Johnson & Johnson, LLC, 1; D. Parenti, Janssen, 3,Johnson & Johnson, LLC, 1; S. Black, Janssen, 3,Johnson & Johnson, LLC, 1; S. Xu, Janssen, 3,Johnson & Johnson, LLC, 1; W. Langholff, Janssen, 3,Johnson & Johnson, LLC, 1; C. O. Bingham III, Janssen, 2,Janssen, 5.

To cite this abstract in AMA style:

Curtis JR, Conaway D, Schechtman J, Broadwell A, Kivitz AJ, Bray V, Kafka S, Parenti D, Black S, Xu S, Langholff W, Bingham III CO. Responsiveness of the Patient Reported Outcomes Measurement Information System to Golimumab Intravenous and Infliximab Treatment in a Real World Clinical Trial in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/responsiveness-of-the-patient-reported-outcomes-measurement-information-system-to-golimumab-intravenous-and-infliximab-treatment-in-a-real-world-clinical-trial-in-rheumatoid-arthritis-patients/. Accessed January 28, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/responsiveness-of-the-patient-reported-outcomes-measurement-information-system-to-golimumab-intravenous-and-infliximab-treatment-in-a-real-world-clinical-trial-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences